Search

everythinglearnresearchcommunity

for

Search:↓

The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It suggests that affordable genetic therapy could be the ultimate solution.

A user shared their hair transformation over four months using daily 2.5mg oral minoxidil, every other day 1mg oral finasteride, weekly dermastamping, and daily scalp massages, with plans for a hair transplant. Another user suggested continuing the medication for a year before considering a transplant.

PP405 is a potential hair loss treatment that may activate dormant hair follicles, but there are concerns about its effectiveness, cost, and side effects. Users discuss treatments like minoxidil, finasteride, and RU58841, expressing skepticism about PP405's long-term success and accessibility.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

A 24-year-old user tried finasteride, oral minoxidil, and dutasteride for hair loss but saw no improvement and was advised by their dermatologist to accept baldness. Other users suggested alternative treatments like RU58841, pyrilutamide, microneedling, and checking for underlying conditions or lifestyle factors.

A 27-year-old actor shared his positive experience with two hair transplant surgeries, highlighting the importance of customization and detail for a natural look. He is taking finasteride to prevent future hair loss.

Some users believe John Harper's hair regrowth claims using dermarolling, coffee, and oils are misleading, while others defend his methods. The conversation highlights skepticism about alternative treatments and emphasizes finasteride, dutasteride, and minoxidil as proven solutions for hair loss.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

The conversation discusses a comprehensive hair regrowth regimen including Dutasteride, Finasteride, microneedling, RU58841, oral and topical Minoxidil, Tretinoin, and Vitamin D3. Suggestions include dropping Finasteride, increasing Dutasteride, and considering additional treatments like caffeine, melatonin, and laser therapy, while emphasizing the effectiveness of Dutasteride and Minoxidil.

The conversation discusses various treatments for hair loss, including minoxidil, finasteride, and topical dutasteride, with users debating their effectiveness and side effects. Despite the treatments, many believe androgenetic alopecia (AGA) ultimately prevails in the long term.

The user is using a comprehensive hair loss treatment including oral dutasteride, minoxidil (both oral and topical), topical finasteride, RU58841, ketoconazole shampoo, and a derma roller, while also using anabolic steroids. Opinions vary, with some users noting stability or slight improvement, while others suggest the treatment may not be effective due to anabolic use.

PP405 shows significantly better early-stage hair regrowth results compared to minoxidil and finasteride, with 31% of users experiencing over 20% density increase in 4–8 weeks. Minoxidil and finasteride show minimal or no visible regrowth in the same timeframe.

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

The conversation humorously suggests that the hair loss industry, referred to as "Big Bald," deliberately delays a cure to profit from ongoing treatments like minoxidil, finasteride, and dutasteride. Participants debate whether a cure would be more profitable than current treatments, with some suggesting that the industry prefers continuous treatments for sustained profit.

Epibiotech will offer off-the-shelf allogeneic hair multiplication treatment in South Korea, using dermal papilla cells from donors to grow hair in balding areas. This method is cheaper and less invasive than traditional hair transplants.

A new study that found a single chemical could potentially be responsible for hair loss, and the potential to use this discovery to stimulate hair growth. The conversation also includes various treatments such as Minoxidil, Finasteride, RU58841, microneedling, DUT, and Botox for hair loss.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. The focus is on setting realistic expectations for these treatments.

The post discusses the confusion about the optimal microneedling depth and frequency for hair growth, and when to apply treatments like minoxidil. A reply suggests the best method is using a 1.25mm depth every 7 days with a specific device, holding it for 10 seconds to stimulate hair growth.

The conversation discusses the use of trichoscopy to predict hair loss patterns and inform treatment approaches. Treatments mentioned include minoxidil, finasteride, and dutasteride, with varying effectiveness based on gender-specific hair loss patterns.

PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also mentions a new hair transplant therapy approved by the government.

OP shares their experience with PCOS-related hair loss, highlighting that addressing vitamin D and ferritin deficiencies, managing hormones with spironolactone, and using gentle hair care products helped improve their condition. They advise against relying on "miracle" hair oils and emphasize the importance of medical evaluation and a combined approach to treatment.

The user is using a hair loss regimen involving 2ddr applied twice daily, tretinoin weekly, and occasionally micro-needling. They report feeling increased scalp thickness and seeing some hair growth progress.

The conversation expresses frustration over the lack of progress in hair loss treatments, with specific mentions of Minoxidil, finasteride, and RU58841. Users discuss the slow development of new treatments and the potential of hair transplants.

Exploring potential treatments for hair loss, such as Minoxidil, Finasteride, RU58841 and Pyrilutamide. The user is looking for feedback on whether KX-826 can be used successfully as a single therapy to stop the miniaturization process.

The conversation is about the delay in the release of GT20029 phase 2 results by Kintor. It also mentions Minoxidil, finasteride, and RU58841 as treatments for hair loss.

DHT may inhibit hair growth by affecting mitochondrial function, leading to hair follicle miniaturization. Treatments like minoxidil and PP405 may promote hair growth by altering metabolic pathways, potentially counteracting DHT's effects.

Botox is found to be as effective as finasteride in treating hair loss. Users discuss combining treatments like botox, minoxidil, and massages for better results.

The user underwent a hair transplant in Boston, initially dissatisfied with the results, but later achieved significant improvement in hair density and natural appearance after consulting a different surgeon. They used finasteride, minoxidil, and low-level laser therapy as part of their treatment.

PP405 is expected to be more expensive than finasteride and minoxidil initially due to patent protection, but not as costly as life-saving medications like Ozempic. The price may decrease after the patent expires, but initially, it might be around $100 per month, making it potentially unaffordable for many.